BeOne Medicines (ONC) Competitors $313.97 +4.64 (+1.50%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ONC vs. SNY, GSK, TAK, ARGX, BNTX, INSM, TEVA, SMMT, GMAB, and VTRSShould you be buying BeOne Medicines stock or one of its competitors? The main competitors of BeOne Medicines include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. BeOne Medicines vs. Its Competitors Sanofi GSK Takeda Pharmaceutical argenex BioNTech Insmed Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations. Which has better valuation and earnings, ONC or SNY? Sanofi has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B9.03-$644.79M-$1.73-181.49Sanofi$44.46B2.80$6.02B$4.1612.17 Do analysts prefer ONC or SNY? BeOne Medicines currently has a consensus price target of $330.89, indicating a potential upside of 5.39%. Sanofi has a consensus price target of $62.00, indicating a potential upside of 22.51%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Sanofi 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.11 Is ONC or SNY more profitable? Sanofi has a net margin of 21.47% compared to BeOne Medicines' net margin of -3.89%. Sanofi's return on equity of 16.86% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-3.89% -1.22% -0.72% Sanofi 21.47%16.86%9.63% Does the media refer more to ONC or SNY? In the previous week, Sanofi had 14 more articles in the media than BeOne Medicines. MarketBeat recorded 26 mentions for Sanofi and 12 mentions for BeOne Medicines. Sanofi's average media sentiment score of 1.02 beat BeOne Medicines' score of 0.32 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 16 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ONC or SNY? 48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, ONC or SNY? BeOne Medicines has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. SummarySanofi beats BeOne Medicines on 13 of the 17 factors compared between the two stocks. Get BeOne Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricBeOne MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.41B$2.49B$5.74B$9.56BDividend YieldN/A1.66%4.53%4.08%P/E Ratio-181.4822.4830.4525.16Price / Sales9.03549.05392.5887.64Price / CashN/A173.7937.0358.50Price / Book9.135.268.956.21Net Income-$644.79M$31.83M$3.26B$265.38M7 Day Performance1.38%0.83%1.06%-1.13%1 Month Performance7.55%3.71%4.31%-0.71%1 Year PerformanceN/A9.37%28.40%18.89% BeOne Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCBeOne Medicines0.687 of 5 stars$313.97+1.5%$330.89+5.4%N/A$34.41B$3.81B-181.4811,000SNYSanofi3.858 of 5 stars$49.77+1.5%$62.00+24.6%-7.8%$120.42B$44.46B11.9682,878Positive NewsGSKGSK2.8893 of 5 stars$39.30+0.2%$37.38-4.9%-3.7%$80.00B$31.63B18.1968,629Positive NewsTAKTakeda Pharmaceutical1.5471 of 5 stars$14.99+1.3%N/A+4.8%$47.09B$30.09B49.9747,455News CoveragePositive NewsShort Interest ↑ARGXargenex3.8459 of 5 stars$653.83+0.2%$746.81+14.2%+26.1%$39.93B$3.05B33.531,599Positive NewsBNTXBioNTech1.6541 of 5 stars$113.52+0.7%$135.80+19.6%+25.7%$27.09B$2.98B-70.956,772Analyst RevisionINSMInsmed4.1144 of 5 stars$127.80+0.0%$129.57+1.4%+69.9%$27.00B$363.71M-22.381,271Trending NewsAnalyst ForecastInsider TradeTEVATeva Pharmaceutical Industries3.5644 of 5 stars$17.86+1.8%$24.71+38.4%-3.7%$20.12B$16.63B-111.6336,830Positive NewsSMMTSummit Therapeutics2.3809 of 5 stars$26.69+0.9%$35.00+31.1%+110.2%$19.65B$700K-26.43110News CoverageAnalyst ForecastGMABGenmab A/S3.8755 of 5 stars$23.31+1.4%$37.60+61.3%-11.5%$14.74B$3.12B11.712,682Positive NewsAnalyst DowngradeAnalyst RevisionVTRSViatris2.0063 of 5 stars$10.61-0.7%$10.40-2.0%-8.7%$12.46B$14.74B-3.6632,000 Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives BNTX Alternatives INSM Alternatives TEVA Alternatives SMMT Alternatives GMAB Alternatives VTRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONC) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access